The CPM platform provides, for the first time, the opportunity to accurately measure an array complement proteins from a single systemically drawn blood sample. This includes C3 and its breakdown products, Factor I, Factor H, FHL-1 as well as the FHR family of proteins. 

The CPM platform will facilitate the stratification of patients with AMD and other conditions for enrolment into future clinical trials as well as supporting the subsequent commercialisation of our assets. 

Presently the CPM platform has been validated in normal human samples and two distinct disease cohorts (Cipriani and Unwin et al., Am J Hum Genet, 2021).